Related Experiment Videos
Aclacinomycin A stabilizes topoisomerase I covalent complexes
J L Nitiss1, P Pourquier, Y Pommier
1Molecular Pharmacology Department, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Cancer Research
|October 23, 1997
Summary
Aclacinomycin A (aclarubicin) inhibits topoisomerase II and stabilizes topoisomerase I, revealing its dual action as a novel anticancer agent. This finding enhances understanding of its therapeutic potential in treating various cancers.
Area of Science:
- Molecular Biology
- Pharmacology
- Oncology
Background:
- Aclacinomycin A (aclarubicin) is an anthracycline anticancer drug with known activity against leukemias and solid tumors.
- Prior research suggested its primary mechanism involves inhibiting topoisomerase II catalytic activity.
Purpose of the Study:
- To validate aclacinomycin A as a topoisomerase II inhibitor in vivo using a yeast system.
- To identify additional cellular targets of aclacinomycin A.
- To investigate the drug's effects on topoisomerase I.
Main Methods:
- Utilized a yeast model system to assess drug resistance and target identification.
- Conducted biochemical analyses with purified human topoisomerase I.
- Evaluated the stabilization of topoisomerase I-DNA covalent complexes.
Main Results:
- Overexpression of yeast topoisomerase II conferred resistance to aclacinomycin A, supporting its role as a catalytic inhibitor.
- Aclacinomycin A was found to stabilize topoisomerase I cleavage in yeast, similar to camptothecin.
- Biochemical assays confirmed that aclacinomycin A efficiently stabilizes human topoisomerase I covalent complexes.
Conclusions:
- Aclacinomycin A functions as a catalytic inhibitor of topoisomerase II in vivo.
- The drug also acts as a novel stabilizer of topoisomerase I covalent complexes.
- Aclacinomycin A represents a new class of anticancer agents with combined topoisomerase I and II inhibitory activity.